FAVOR II China Study Examines Diagnostic Accuracy of Quantitative Flow Ratio

October 31, 2017—The FAVOR II China trial evaluated the diagnostic accuracy of quantitative flow ratio (QFR) in diagnosing hemodynamically significant coronary stenosis as defined by fractional flow reserve (FFR). QFR is an angiography-based method for deriving FFR without a pressure wire or induction of hyperemia. Findings from FAVOR II were presented during a First Report Investigations session at TCT 2017, the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium held October 30 to November 2 in Denver, Colorado.

The TCT announcement advised that 308 patients were enrolled in the study between June and July 2017. Patient-level and vessel-level diagnostic accuracy of QFR were 92.4% (95% confidence interval [CI], 88.9%–95.1%) and 92.7% (95% CI, 89.3%–95.3%), both significantly higher than the prespecified target value (P < .001). The sensitivity and specificity in identifying hemodynamically significant stenosis were significantly higher for QFR than quantitative coronary angiography.

In the TCT press release, Bo Xu, MBBS, commented, “FAVOR II China showed that QFR has high feasibility and accuracy in identifying hemodynamically significant coronary stenosis. It also demonstrates the clinical utility of QFR for use in diagnostic catheterization laboratories. QFR has the potential to improve angiography-based identification of functionally significant stenosis during coronary angiography.”

The FAVOR II CHINA trial was funded by Pulse Medical Imaging Technology (Shanghai) Co., Ltd, the National Key Research and Development Program of China, and the Natural Science Foundation of China, advised TCT.